4 Ways Precision Medicine Impacts Cancer Treatment
Precision medicine is a potential game-changer and oncology expert Jeremy Schafer offers four ways that he believes precision medicine will change cancer treatment.
Read the full article here.
Chou and Stillerman Talk Value Assessments in MedAd News
In a new MedAd News feature article on the influence of value assessments, Precision Xtract’s Jacki Chou and Zac Stillerman provide their insights on the growing influence of ICER, and how manufacturers can be more proactive in shaping favorable assessments of their new treatments.
FDA Unveils Final Interchangeability Guidance for Biosimilars
The FDA has finally released its guidance on biosimilar interchangeability. Radar on Specialty Pharmacy speaks with Ryan Cox, Precision for Value Vice President, Access Experience team on how the new guidelines reduce administrative hurdles and duplicative clinical trials. However, he notes that reimbursement issues may discourage uptake.
Zolgensma Adds to SMA Options but Raises Multiple Questions
With the FDA’s approval of Zolgensma, the industry receives another data point in the pricing strategies for new gene therapies. As reported in Radar on Specialty Pharmacy, the two payment options offered by AveXis, makers of Zolgensma, both follow the movement to value-based purchasing. Larry Blandford, executive vice president of Precision Value and Health, discusses the rationale for and potential issues of these strategies.
Despite Drug Approvals, Generics Remain Depression Mainstay
Despite recent approval of the first new treatment for depression in years, most patients will still use one of the many generics on the market. As reported in Health Plan Weekly, step therapy and generics-first strategies will continue to prevail. Kellie Rademacher, Vice President, Experience and Access Team, Precision for Value, comments.
CBO says Proposed Rule to Kill Rebates Will Increase Spending by $177 Billion
Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
CBO says Proposed Rebate Rule Will Cost Government $177B
HHS wants to eliminate drug rebates in Medicare Part D and Medicaid managed care. But the CBO projects the resulting higher premiums will cost the government dearly. In an AIS Health, Radar on Specialty Pharmacy article, Jeremy Schafer, Precision for Value Senior Vice President, Access Experience, weighs in on the potential impact of the rule, and what that means for its future. (more…)
Generic Advair May Help COPD Costs, but Management is Tough
When high out-of-pocket costs spur noncompliance that leads to increased hospitalization, payers take notice. Using therapies for COPD as a case in point, AIS Health, Radar on Drug Benefits interviews Precision for Value Vice President, Access Experience, Charline Shan about the strategies payers may take to lower costs for their beneficiaries—and themselves.
New RA biosimilar impact hinges on patent lawsuit
The launch of a new RA biosimilar is being held up in court—and the outcome of the lawsuit will have far-reaching impact on prices. Jeremy Schafer, Precision for Value Senior Vice President and director of the Access Experience Team, explains why in formularywatch.
Getting Personal with Precision Medicine
The definition of personalized medicine has expanded beyond tailored medical treatment to encompass drug development, care delivery and consumer engagement—while precision medicine refers to the tailoring of medical treatment to the characteristics of a patient subpopulation. This PharmaVoice cover story explores the distinctions, the challenges and the implications, including insights from Precision for Medicine’s own Chad Clark.
